Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea; Department of Surgery, College of Medicine, Seoul National University, Seoul, South Korea.
Surg Oncol. 2020 Jun;33:63-69. doi: 10.1016/j.suronc.2020.01.001. Epub 2020 Jan 14.
Laparoscopic liver resection(LLR) for intrahepatic cholangiocarcinoma is debatable due to technical challenges associated with major hepatectomy and lymph node dissection. This study aims to analyze the long-term outcomes with propensity score matching.
Patients who underwent liver resection for intrahepatic cholangiocarcinoma from August 2004 to October 2015 were enrolled. Those who had combined hepatocellular-cholangiocarcinoma and palliative surgery were excluded. Medical records were reviewed for postoperative outcome, recurrence, and survival. The 3-year disease-free survival(DFS) and 3-year overall survival(OS) were set as the primary endpoint, and 3-year disease-specific survival, 1-year OS, 1-year DFS, operative outcome, and postoperative complications were secondary endpoints.
A total of 91 patients were enrolled with 61 in the open group and 30 in the laparoscopic group. Propensity score matching included 24 patients in both groups. In total, the 3-year OS was 81.2% in the open group and 76.7% in the laparoscopic group(p = 0.621). For 3-year DFS, open was 42.5% and laparoscopic was 65.6%(p = 0.122). Mean operation time for the open group was 343.2 ± 106.0 min and laparoscopic group was 375.2 ± 204.0 min(p = 0.426). Hospital stay was significantly shorter in the laparoscopic group(9.8 ± 5.1 days) than the open group(18.3 ± 14.7, p=<0.001). There was no difference in complication rate and 30-day readmission rate. Tumor size, nodularity, and presence of perineural invasion showed an independent association with the 3-year DFS in multivariate analysis.
Laparoscopic liver resection for intrahepatic cholangiocarcinoma is technically feasible and safe, providing short-term benefits without increasing complications or affecting long-term survival.
由于与肝切除术和淋巴结清扫相关的技术挑战,腹腔镜肝切除术(LLR)治疗肝内胆管细胞癌仍存在争议。本研究旨在通过倾向评分匹配分析长期结果。
纳入 2004 年 8 月至 2015 年 10 月期间因肝内胆管细胞癌接受肝切除术的患者。排除合并肝细胞癌和姑息性手术的患者。回顾性分析术后结果、复发和生存情况。以 3 年无病生存率(DFS)和 3 年总生存率(OS)为主要终点,以 3 年疾病特异性生存率、1 年 OS、1 年 DFS、手术结果和术后并发症为次要终点。
共纳入 91 例患者,其中开放组 61 例,腹腔镜组 30 例。两组均采用倾向评分匹配纳入 24 例患者。总的来说,开放组 3 年 OS 为 81.2%,腹腔镜组为 76.7%(p=0.621)。3 年 DFS 方面,开放组为 42.5%,腹腔镜组为 65.6%(p=0.122)。开放组的平均手术时间为 343.2±106.0min,腹腔镜组为 375.2±204.0min(p=0.426)。腹腔镜组的住院时间明显短于开放组(9.8±5.1 天对 18.3±14.7 天,p<0.001)。两组并发症发生率和 30 天再入院率无差异。多因素分析显示,肿瘤大小、结节性和神经周围侵犯与 3 年 DFS 独立相关。
腹腔镜肝切除术治疗肝内胆管细胞癌在技术上是可行和安全的,提供了短期获益,不会增加并发症或影响长期生存。